Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/27873
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Ask, Kjetil | - |
dc.contributor.author | Revill, Spencer | - |
dc.date.accessioned | 2022-09-26T21:18:07Z | - |
dc.date.available | 2022-09-26T21:18:07Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.uri | http://hdl.handle.net/11375/27873 | - |
dc.description.abstract | Histological and visual assessment of pulmonary fibrosis are used as a gold standard to determine severity of fibrotic lung disease. The Ashcroft scoring technique and histological stains like Masson’s trichrome and picrosirius red (PSR) have been used for decades as primary readouts, often alongside a biochemical assay estimating the amount of hydroxyproline in the tissue. As pulmonary fibrosis is a heterogeneous disease and collagen content rarely shows more than a two-fold increase between a non-diseased and a diseased lung, therapeutic assessment is challenging due to the variability animal models. To improve the assessment of the severity of fibrotic lung disease, we have developed models using multivariate linear regression and XGBoost machine learning that consider digital quantifications of histological features from 73 clinically diagnosed cases of IPF and 11 control tissues, obtained using the HALO® platform, that correlate with the Ashcroft score and combine them into a composite index that we believe represents a better, more objective way of scoring fibrotic lung tissues. The tissues were stained with H&E for structural assessment, Trichrome (TRI), and Picrosirius Red (PSR) for collagen content, alpha-smooth muscle actin (αSMA) to assess the amount of ECM-producing myofibroblasts (MFBs), and CD68, CD163, and CD206 for macrophage content and activation as they have been correlated with lung fibrosis and are considered a therapeutic target. | en_US |
dc.language.iso | en | en_US |
dc.subject | Fibrosis, Lung, Histology, Digital Pathology, HALO®, Composite Index, Model, Machine Learning | en_US |
dc.title | DEVELOPING A HISTOLOGY-BASED COMPOSITE INDEX TO ASSESS THE DEGREE OF LUNG FIBROSIS USING QUANTITATIVE HALO® MODULES | en_US |
dc.title.alternative | USING QUANTITATIVE HISTOLOGICAL READOUTS OF PULMONARY FIBROSIS TO PRODUCE A SCORE OF FIBROTIC LUNG DISEASE SEVERITY | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Medical Sciences | en_US |
dc.description.degreetype | Thesis | en_US |
dc.description.degree | Master of Science (MSc) | en_US |
dc.description.layabstract | Lung diseases involving excess scar tissue formation resulting in lung failure are difficult to study, especially when the most used method for assessing the progression of the disease, the Ashcroft score, is imprecise and subject to bias. The goal with this project is to update this current gold standard for rating disease severity in a portion of lung from the purely visual Ashcroft score to one that uses robust computational methods. This novel method uses digital pathology software, HALO®, to quantify components of the lung tissue, such as population densities of specific cell types, the proportion of alveolar airspace to alveolar interstitium, and the extent of scarring in the lung according to collagen content. Then, machine learning is used to generate a severity score that resembles the standard method, and should feel familiar to lung researchers, but that we believe is more reliable and would be consistent between research groups. | en_US |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
revill _spencer_d_finalsubmission202209_masterofscience.pdf | 6.37 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.